antidiabetic actions non-agonist ppar gamma ligand blocking cdk5-mediated phosphorylation 
ppar gamma functioning receptor thiazolidinedione tzd class antidiabetes drugs including rosiglitazone pioglitazone drugs full classical agonists nuclear receptor recent data shown many ppar gamma-based drugs separate biochemical activity blocking obesity-linked phosphorylation ppar gamma cdk5 ref describe novel synthetic compounds unique mode binding ppar gamma completely lack classical transcriptional agonism block cdk5-mediated phosphorylation cultured adipocytes insulin-resistant mice moreover one compound sr1664 potent antidiabetic activity causing fluid retention weight gain serious side effects many ppar gamma drugs unlike tzds sr1664 also interfere bone formation culture data illustrate new classes antidiabetes drugs can developed specifically targeting cdk5-mediated phosphorylation ppar gamma 
